SuperworthARS Pharmaceuticals EPS SPRY
Diluted earnings per share by quarter and over the last twelve months, from 2020.
- Last 12 months, to Jun 30, 2026
- −$2.18
- Latest quarter, Q2 FY26
- −$0.63
- Fiscal year 2025
- −$1.75
- −3600% on the year before
ARS Pharmaceuticals' earnings per share was −$2.18 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$0.63.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$1.75 | −3600% |
| FY2024 | $0.05 | n/a |
| FY2023 | −$0.57 | n/a |
| FY2022 | −$0.87 | n/a |
| FY2021 | −$2.56 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.63 | n/a | −$2.18 | |
| Q1 FY26 | −$0.61 | n/a | −$2.01 | |
| Q4 FY25 | −$0.42 | −186% | −$1.75 | |
| Q3 FY25 | −$0.52 | n/a | −$0.84 | |
| Q2 FY25 | −$0.46 | n/a | −$0.52 | |
| Q1 FY25 | −$0.35 | n/a | −$0.19 | |
| Q4 FY24 | $0.49 | n/a | $0.05 | |
| Q3 FY24 | −$0.20 | n/a | −$0.51 | |
| Q2 FY24 | −$0.13 | n/a | −$0.47 | |
| Q1 FY24 | −$0.11 | n/a | −$0.52 | |
| Q4 FY23 | −$0.07 | n/a | −$0.57 | |
| Q3 FY23 | −$0.16 | n/a | −$0.71 |
Against its peers
Companies in Drug Manufacturers - General nearest ARS Pharmaceuticals' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| SPRYARS Pharmaceuticals | −$2.18 | |
| ARVNArvinas | $0.16 | |
| PBYIPuma Biotechnology | $0.52 | −47% a year |
| IRWDIronwood Pharmaceuticals | $0.77 | |
| ZVRAZevra Therapeutics | $0.93 | |
| CRMDCorMedix | $2.13 | +184% a year |
| COLLCollegium Pharmaceutical | $1.24 | +19% a year |
| NATRNatures Sunshine Products | $1.01 | +36% a year |
| ABUSArbutus Biopharma | $0.78 | |
| AMPHAmphastar Pharmaceuticals | $1.70 | −36% a year |
| OMEROmeros | $1.52 | |
| Peer median | $0.97 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on ARS Pharmaceuticals
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.